跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection - TGA Drug Approval Details
Approvals
/
TGA
/
OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection
Approved
STANDARD
OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection
Maxx Pharma Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
359dfe753f0dbf22
Company
Maxx Pharma Pty Ltd
Type
Standard
Approval Details
Approval Id
359dfe753f0dbf22
Product Name
OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection
Artg Id
288223
Artg Name
OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection
Sponsor
Maxx Pharma Pty Ltd
Company Detail Path
/organization/maxx-pharma-pty-ltd
Artg Date
2018-12-11
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/a1811238de9d0e28753eaed58556131e.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/c6fe51b9645d0783b9b704e1b2d1a0fe.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
359dfe753f0dbf22
Type
Standard
Back to TGA Approvals